Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company granted stock options to purchase up to 50,000 shares of common stock to four new employees under its 2023 Inducement Plan.
The stock options feature a four-year vesting schedule, with 25% of shares vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months. Continued employment with Syndax is required through applicable vesting dates.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale focalizzata sulle terapie contro il cancro, ha annunciato concessioni di indennità secondo la Regola di Quotazione NASDAQ 5635(c)(4). L'azienda ha concesso opzioni su azioni per l'acquisto di fino a 50.000 azioni ordinarie a quattro nuovi dipendenti nell'ambito del suo Piano di Indennità 2023.
Le opzioni su azioni prevedono un programma di maturazione di quattro anni, con il 25% delle azioni che matura dopo il primo anno e le restanti azioni che maturano mensilmente a 1/48 nel successivo periodo di 36 mesi. È richiesta la continuazione dell'impiego con Syndax fino alle date di maturazione applicabili.
Syndax Pharmaceuticals (NASDAQ: SNDX), una empresa biofarmacéutica en etapa comercial centrada en terapias contra el cáncer, ha anunciado concesiones de inducción bajo la Regla de Listado NASDAQ 5635(c)(4). La compañía otorgó opciones sobre acciones para comprar hasta 50,000 acciones ordinarias a cuatro nuevos empleados bajo su Plan de Inducción 2023.
Las opciones sobre acciones cuentan con un programa de adquisición de cuatro años, con el 25% de las acciones que se adquieren después del primer año y las acciones restantes que se adquieren mensualmente a 1/48 en los siguientes 36 meses. Se requiere continuar el empleo con Syndax hasta las fechas de adquisición aplicables.
신닥스 제약(Syndax Pharmaceuticals) (NASDAQ: SNDX), 암 치료에 집중하는 상업 단계의 생명공학 회사가 NASDAQ 상장 규칙 5635(c)(4)에 따라 유인 보상을 발표했습니다. 이 회사는 2023 유인 계획에 따라 네 명의 새로운 직원에게 50,000주의 보통주를 구매할 수 있는 주식 옵션을 부여했습니다.
주식 옵션은 4년의 베스팅 일정을 특징으로 하며, 첫 해가 끝난 후 25%의 주식이 베스팅되고 나머지 주식은 이후 36개월 동안 매달 1/48씩 베스팅됩니다. 해당 베스팅 날짜까지 신닥스에서 계속 근무해야 합니다.
Syndax Pharmaceuticals (NASDAQ: SNDX), une entreprise biopharmaceutique en phase commerciale axée sur les thérapies contre le cancer, a annoncé des subventions d'incitation conformément à la Règle de Cotation NASDAQ 5635(c)(4). L'entreprise a accordé des options d'achat d'actions pour un total de 50 000 actions ordinaires à quatre nouveaux employés dans le cadre de son Plan d'Incitation 2023.
Les options d'achat d'actions présentent un calendrier d'acquisition de quatre ans, avec 25 % des actions acquises après la première année et les actions restantes acquises mensuellement à raison de 1/48 au cours des 36 mois suivants. Un emploi continu chez Syndax est requis jusqu'aux dates d'acquisition applicables.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Krebsbehandlungen konzentriert, hat Induktionszuschüsse gemäß der NASDAQ-Listing-Regel 5635(c)(4) angekündigt. Das Unternehmen hat vier neuen Mitarbeitern Aktienoptionen zum Kauf von bis zu 50.000 Aktien des Stammkapitals im Rahmen seines Induktionsplans 2023 gewährt.
Die Aktienoptionen verfügen über einen vierjährigen Vesting-Zeitplan, wobei 25 % der Aktien nach dem ersten Jahr und die verbleibenden Aktien monatlich im Verhältnis 1/48 über die folgenden 36 Monate vesten. Eine fortgesetzte Anstellung bei Syndax ist bis zu den entsprechenden Vesting-Daten erforderlich.
- None.
- None.
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
How many shares were granted in Syndax Pharmaceuticals' (SNDX) April 2025 inducement awards?
What is the vesting schedule for SNDX's April 2025 inducement stock options?
How many employees received SNDX stock options in the April 2025 inducement grants?
Under which plan did Syndax (SNDX) issue its April 2025 inducement grants?
